Abstract
The nicotinic acetylcholine receptors (nAChR) are ligand-gated ion channels involved in cognitive processes and are associated with brain disorders which makes them interesting drug targets. This article presents a general overview of the receptor to introduce the α7 nAChR as a drug target. The advances in understanding of the structure/function properties of the nAChR produced during the last decade are detailed as they are crucial for rational drug design. The allosteric properties of the nAChR will also be described because they also have important consequences for drug design.
Keywords: α7-Nicotinic Acetylcholine Receptors, Alzheimer disease, tobacco dependance, schizophrenia, cognitive processes, allosteric, deug design, bacteria, prokaryotic LGIC, AChBP
Current Drug Targets
Title:α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Volume: 13 Issue: 5
Author(s): Antoine Taly, Sebastien Charon
Affiliation:
Keywords: α7-Nicotinic Acetylcholine Receptors, Alzheimer disease, tobacco dependance, schizophrenia, cognitive processes, allosteric, deug design, bacteria, prokaryotic LGIC, AChBP
Abstract: The nicotinic acetylcholine receptors (nAChR) are ligand-gated ion channels involved in cognitive processes and are associated with brain disorders which makes them interesting drug targets. This article presents a general overview of the receptor to introduce the α7 nAChR as a drug target. The advances in understanding of the structure/function properties of the nAChR produced during the last decade are detailed as they are crucial for rational drug design. The allosteric properties of the nAChR will also be described because they also have important consequences for drug design.
Export Options
About this article
Cite this article as:
Antoine Taly, Sebastien Charon , α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398919
DOI https://dx.doi.org/10.2174/138945012800398919 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
Clinical Cancer Drugs Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Hyaluronan and Hyaluronan Synthases: Potential Therapeutic Targets in Cancer
Current Drug Targets - Cardiovascular & Hematological Disorders Investigative Approaches for Oral Delivery of Anticancer Drugs: A Patent Review
Recent Patents on Drug Delivery & Formulation How Inhaled Asbestos Causes Scarring and Cancer
Current Respiratory Medicine Reviews Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer
Current Cancer Drug Targets STING Activation and its Application in Immuno-Oncology
Current Topics in Medicinal Chemistry Onconase and Amphinase, the Antitumor Ribonucleases from Rana pipiens Oocytes
Current Pharmaceutical Biotechnology Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Compound Ranking Based on a New Mathematical Measure of Effectiveness Using Time Course Data from Cell-Based Assays
Combinatorial Chemistry & High Throughput Screening Subject Index to Volume 4
Current Medicinal Chemistry - Anti-Cancer Agents Targeting T Cell Metabolism as a Novel Approach for Treatment of MS: With a Focus on PFKFB3 Inhibitors
Endocrine, Metabolic & Immune Disorders - Drug Targets Quercetin: A Comprehensive Review
Current Nutrition & Food Science ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies
Current Drug Delivery Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Current Medicinal Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets